Roth Capital Lowers Earnings Estimates for Journey Medical

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital dropped their Q1 2025 EPS estimates for shares of Journey Medical in a report released on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The company had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million.

Separately, Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.67.

Journey Medical Stock Performance

DERM opened at $6.11 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The firm has a market cap of $127.64 million, a PE ratio of -6.50 and a beta of 0.97. The business has a fifty day simple moving average of $5.09 and a 200-day simple moving average of $5.17. Journey Medical has a fifty-two week low of $3.20 and a fifty-two week high of $6.89.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Cetera Investment Advisers increased its holdings in Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after buying an additional 2,478 shares during the last quarter. PVG Asset Management Corp grew its position in Journey Medical by 5.7% in the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after acquiring an additional 9,005 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in shares of Journey Medical during the 3rd quarter worth $66,000. Geode Capital Management LLC raised its holdings in shares of Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after purchasing an additional 12,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Journey Medical in the 4th quarter valued at $80,000. 7.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 18,147 shares of Journey Medical stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11. Following the completion of the sale, the chief executive officer now owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. This trade represents a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 105,831 shares of company stock valued at $536,622 over the last three months. 13.16% of the stock is owned by corporate insiders.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.